Betrixaban is a Factor Xa inhibitor used for prophylaxis of venous thromboembolism in hospitalized patients. Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa.
- Mechanism
- Curator reviewed · 1 reference
Betrixaban is a cofactor-independent direct inhibitor of the Factor Xa and inhibits free and prothrombinase-bound Factor Xa.
- Primary indication
- Betrixaban is indicated for prophylaxis of venous thromboembolism (VTE) in conditions of moderate to severe restricted mobility or in patients that qualify as in risk of VTE.Curator reviewed · 1 structured indication
- Formula / weight
- C23H22ClN5O3 · 451.91 g/mol (avg)
- First approval
- United States, 2017
- Code names
- PRT-054021
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
XHOLNRLADUSQLD-UHFFFAOYSA-NSMILESCOC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1Targets
Transporters
What you can answer from here — as of November 06, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
2TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Betrixaban, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account